



cancers

Dear Colleagues,

We are pleased to announce the winners of the *Cancers* 2021 Best Paper Award. All papers published from 1 January 2021 to 31 December 2021 in *Cancers* were considered for the award. After a thorough evaluation of the originality and significance of the papers, citations, and downloads, four winners were selected.

2021 BEST PAPER AWARD WINNERS

Two Reviews:

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer

By Alessandro Rizzo et al.

Cancers **2021**, *13*(3), 558; doi: 10.3390/cancers13030558

STING Agonists as Cancer Therapeutics

By Afsaneh Amouzegar and Jason J. Luke et al.

Cancers **2021**, *13*(11), 2695; doi: 10.3390/cancers13112695

Two Articles:

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

By Christian Sordo-Bahamonde, Ana P. González-Rodríguez and Segundo Gonzalez et al.

Cancers **2021**, *13*(9), 2112; doi: 10.3390/cancers13092112

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

By Matteo Bauckneht et al.

Cancers **2021**, *13*(13), 3117; doi: 10.3390/cancers13133117

Each winner will receive CHF 500 and a chance to publish a paper free of charge in *Cancers* in 2023 after peer review.

Please join us in congratulating the winners of the *Cancers* 2021 Best Paper Award. We would also like to take this opportunity to thank all of our authors for your continued support of *Cancers*.

